



Advances in Cancer Cachexia

Guest Editors:

Dr. Sander S. Rensen

Department of Surgery,
Maastricht University Medical
Centre, Maastricht, The
Netherlands

**Prof. Dr. Steven W. M. Olde
Damink**

Departments of Surgery, NUTRIM
School of Nutrition and
Translational Research in
Metabolism, Maastricht
University, P.O. Box 616, 6200 MD
Maastricht, The Netherlands

Dr. David P.J. Van Dijk

Department of Surgery,
Maastricht University Medical
Centre, Maastricht, The
Netherlands

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editors

In this Special Issue of *Cancers*, we aim to publish a collection of manuscripts that further our understanding of cancer cachexia and provide novel approaches of assessing cachexia severity, thereby advancing our insights into the factors that play a role in its development and enabling clinical trials with better cachexia phenotyping. In particular, we are looking for papers that describe:

- Development of novel translational models of cancer cachexia (e.g., organoids or new mouse models with slower cachexia progression);
- The role of inflammation and immune cell activation in cancer cachexia;
- The role of the liver and of insulin resistance in cancer cachexia;
- Myosteatosis and other body composition changes in patients with cancer cachexia;
- Artificial intelligence-based approaches to body composition analysis;
- Use of wearables to assess cachexia severity;
- Relationship between body composition and immunotherapy outcomes;
- Prehabilitation approaches to improve therapeutic outcome of cachectic patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)